Cargando…

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative

The phosphoinositide 3-kinase (PI3K) pathway plays a key role in cancer, influencing growth, proliferation, and survival of tumor cells. PIK3CA mutations are generally oncogenic and responsible for uncontrolled cellular growth. PI3K inhibitors (PI3Ki) can inhibit the PI3K/AKT/mTOR pathway, although...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ascione, Liliana, Zagami, Paola, Nicolò, Eleonora, Crimini, Edoardo, Curigliano, Giuseppe, Criscitiello, Carmen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694420/ https://www.ncbi.nlm.nih.gov/pubmed/36579519 http://dx.doi.org/10.3390/jpm12111793

Ejemplares similares

Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
por: Ascione, Liliana, et al.
Publicado: (2023)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer
por: Qian, Jianchang, et al.
Publicado: (2016)

Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls
por: Morganti, Stefania, et al.
Publicado: (2022)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
por: Zattarin, Emma, et al.
Publicado: (2023)

Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards
por: Crimini, Edoardo, et al.
Publicado: (2022)

Management of Cardiac Toxicity Induced by Chemotherapy
por: Trapani, Dario, et al.
Publicado: (2020)

Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
por: Vollbrecht, Claudia, et al.
Publicado: (2022)

Antibody–Drug Conjugates for the Treatment of Breast Cancer
por: Corti, Chiara, et al.
Publicado: (2021)

A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer
por: Anderson, Elizabeth J., et al.
Publicado: (2020)

Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer
por: Diao, Fei-Yu
Publicado: (2021)

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
por: Fusco, Nicola, et al.
Publicado: (2021)

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets
por: Lammers, Philip, et al.
Publicado: (2014)

Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer
por: Curigliano, Giuseppe, et al.
Publicado: (2023)

The HER2-low revolution in breast oncology: steps forward and emerging challenges
por: Nicolò, Eleonora, et al.
Publicado: (2023)

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer
por: Turner, Stuart, et al.
Publicado: (2021)

PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials
por: Fillbrunn, Mirko, et al.
Publicado: (2022)

How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?
por: Morganti, S., et al.
Publicado: (2022)

Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
por: Giugliano, Federica, et al.
Publicado: (2023)

Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies
por: Belli, Carmen, et al.
Publicado: (2022)

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(−) advanced breast cancer: results from BOLERO-2
por: Moynahan, Mary Ellen, et al.
Publicado: (2017)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
por: Jacobson, Anne
Publicado: (2022)

Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
por: Fabi, Alessandra, et al.
Publicado: (2022)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
por: Antonarelli, G., et al.
Publicado: (2023)

Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project
por: Peixoto, Ana, et al.
Publicado: (2023)

SARS-CoV-2 vaccines for cancer patients: a call to action
por: Corti, Chiara, et al.
Publicado: (2021)

Expression of tumor-associated antigens in breast cancer subtypes
por: Curigliano, Giuseppe, et al.
Publicado: (2019)

Endovascular Thrombectomy >24-hr From Stroke Symptom Onset
por: Manning, Nathan W., et al.
Publicado: (2018)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
por: Shikata, Shohei, et al.
Publicado: (2023)

Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials
por: Trillo Aliaga, Pamela, et al.
Publicado: (2021)

Long non-coding RNA00544 serves as a potential novel predictive and prognostic marker for HR+ HER2− subtype breast cancer
por: Liu, Lei, et al.
Publicado: (2017)

A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age
por: Yu, Jing, et al.
Publicado: (2021)

Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method
por: Parikh, Purvish, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_odfe9tcb048pns9o0mtmtm6ioi